AcuCort AB (publ) (XSAT:ACUC)

Sweden flag Sweden · Delayed Price · Currency is SEK
0.591
-0.006 (-1.01%)
At close: Dec 5, 2025
-15.09%
Market Cap 138.56M
Revenue (ttm) 8.63M
Net Income (ttm) -26.93M
Shares Out 234.44M
EPS (ttm) -0.16
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 81,153
Average Volume 271,623
Open 0.586
Previous Close 0.597
Day's Range 0.570 - 0.591
52-Week Range 0.500 - 0.990
Beta 1.32
RSI 47.94
Earnings Date Nov 14, 2025

About AcuCort AB

AcuCort AB (publ) develops and commercializes glucocorticoid dexamethasone films for the treatment of acute allergic conditions. It offers Zeqmelit, a medicine used for the treatment of severe and acute allergic reactions, croup in children, and chemotherapy-induced nausea and vomiting, as well as for the treatment of COVID-19 patients who need supplemental oxygen treatment. AcuCort AB (publ) was incorporated in 2006 and is based in Lund, Sweden. [Read more]

Industry Pharmaceutical Preparations
Founded 2006
Employees 4
Stock Exchange Spotlight Stock Market
Ticker Symbol ACUC
Full Company Profile

Financial Performance

In 2024, AcuCort AB's revenue was 7.72 million, an increase of 17.07% compared to the previous year's 6.59 million. Losses were -17.40 million, 27.1% more than in 2023.

Financial Statements

News

There is no news available yet.